An interventional study of App-based exercise intervention in Primary Antibody Deficiency Disorders, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Yale University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Primary Immunodeficiency Diseases with a site in United States — 25 open to participants now, 34 under way, 4 of them phase 3. Primary Immunodeficiency Diseases · United States.
Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, this one is the 57th largest by planned enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, reaches primary completion later than 14 of the 28 other live ones, and was the 108th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →25 of the 108 studies in Primary Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Shwachman-Diamond Syndrome Alliance Inc · Sites in United States
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–120 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Men only
Children's National Research Institute · Sites in United States
Ages 3 mo–80 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 26 · Phase 3 34 · Phase 4 8
First in 1991; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 40 across the 75 interventional studies, 343 across the 31 observational. Of the 65 that completed or were terminated, 38 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 108 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 1 study filed under Primary Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
11 of the studies in Primary Immunodeficiency Diseases with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03266627New York Medical CollegeAdenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection | 2026-12-31 |
| NCT03266640New York Medical CollegeVirus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if a 12-week exercise program is safe, practical, and acceptable for adults with primary antibody deficiencies. It also looks at whether the program can improve the quality of life and help the immune system work better.
Study activities will include:
Completion of health questionnaires Participation in a 12-week exercise program using a mobile application Having your exercise activity tracked through the mobile application Reporting any symptoms or infections that develop Providing blood samples for immune-related testing at your patient visits. Completion of assessments at the beginning and end of study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12-week, app-based exercise intervention in adults with primary antibody deficiencies with completion of survey procedures and collection of clinical and laboratory data
Behavioral: App-based exercise intervention
12 week structured moderate-intensity exercise intervention delivered via a mobile application
Recruitment rate
Number and proportion of eligible individuals who enroll
Time frame: Day 1
Retention rate
Number of enrolled participants who complete the 12-week study
Time frame: 12 weeks
Frequency of app usage- Adherence
Mean number of times app was utilized
Time frame: 12 weeks
Duration of workout- Adherence
Mean duration of workout in minutes
Time frame: 12 weeks
Mean score Borg Scale of Rating of Perceived Exertion
Measures exertion on a total scale of 0 (no exertion or resting) to 10 (pushing yourself to the max).
Time frame: 12 weeks
Data completeness
Proportion of expected study data successfully collected at each time point
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →